Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Top Cited Papers
- 21 November 2011
- journal article
- review article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Pharmacological Reviews
- Vol. 64 (1), 102-146
- https://doi.org/10.1124/pr.111.004994
Abstract
Statins, among the most commonly prescribed drugs worldwide, are cholesterol-lowering agents used to manage and prevent cardiovascular and coronary heart diseases. Recently, a multifaceted action in different physiological and pathological conditions has been also proposed for statins, beyond anti-inflammation and neuroprotection. Statins have been shown to act through cholesterol-dependent and -independent mechanisms and are able to affect several tissue functions and modulate specific signal transduction pathways that could account for statin pleiotropic effects. Typically, statins are prescribed in middle-aged or elderly patients in a therapeutic regimen covering a long life span during which metabolic processes, aging, and concomitant novel diseases, including cancer, could occur. In this context, safety, toxicity, interaction with other drugs, and the state of health have to be taken into account in subjects treated with statins. Some evidence has shown a dichotomous effect of statins with either cancer-inhibiting or -promoting effects. To date, clinical trials failed to demonstrate a reduced cancer occurrence in statin users and no sufficient data are available to define the long-term effects of statin use over a period of 10 years. Moreover, results from clinical trials performed to evaluate the therapeutic efficacy of statins in cancer did not suggest statin use as chemotherapeutic or adjuvant agents. Here, we reviewed the pharmacology of the statins, providing a comprehensive update of the current knowledge of their effects on tissues, biological processes, and pathological conditions, and we dissected the disappointing evidence on the possible future use of statin-based drugs in cancer therapy.Keywords
This publication has 505 references indexed in Scilit:
- The IFN‐γ‐induced transcriptional program of the CIITA gene is inhibited by statinsEuropean Journal of Immunology, 2008
- Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-κB pathwayBiochemical Pharmacology, 2008
- Fibrate and Statin Synergistically Increase the Transcriptional Activities of PPARα/RXRα and Decrease the Transactivation of NFκBBiochemical and Biophysical Research Communications, 2002
- Inhibition of LOX-1 by Statins May Relate to Upregulation of eNOSBiochemical and Biophysical Research Communications, 2001
- Pitavastatin Enhanced BMP-2 and Osteocalcin Expression by Inhibition of Rho-Associated Kinase in Human OsteoblastsBiochemical and Biophysical Research Communications, 2001
- Compactin and Simvastatin, but Not Pravastatin, Induce Bone Morphogenetic Protein-2 in Human Osteosarcoma CellsBiochemical and Biophysical Research Communications, 2000
- Pharmacodynamic Effects and Pharmacokinetics of Atorvastatin after Administration to Normocholesterolemic Subjects in the Morning and EveningThe Journal of Clinical Pharmacology, 1996
- Effect of Age and Gender on Pharmacokinetics of Atorvastatin in HumansThe Journal of Clinical Pharmacology, 1996
- Effect of Food on the Bioavailability of Atorvastatin, an HMG‐CoA Reductase InhibitorThe Journal of Clinical Pharmacology, 1995
- Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and LovastatinThe Journal of Clinical Pharmacology, 1990